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Summary
Angiogenesis inhibitors are a novel class of promising therapeutic agents for treating cancer. TNP-470, a systemic analogue
of fumagillin, is an angiogenesis inhibitor capable of suppressing the tumorigenicity in several animal models even though
the mechanisms of action have not been completely clarified. In the current study, we investigated the effects of TNP-470
on human fibrosarcoma cells in vivo and in vitro. The administration of TNP-470 could suppress the tumorigenicity of
HT1080 fibrosarcoma tumor. The conditioned medium from HT1080 fibrosarcoma cells treated with TNP-470 inhibited
the proliferation and migration of human endothelial cell line, HUVEC and ECV304. The concentration of VEGF in the
conditioned medium from HT1080 cells treated with TNP-470 was lower than that of the cells without TNP-470 treatment,
indicating that TNP-470 downregulates the secretion of VEGF from HT1080 cells. These findings strongly suggest that the
direct action of TNP-470 on sarcoma cells inhibits angiogenesis through the downregulation of VEGF secretion and this
angiogenesis suppression resulted in the inhibition of tumorigenicity of HT1080 fibrosarcoma tumor.
Introduction
Soft tissue sarcoma is a rare neoplasm which arise
mainly in extremity or retroperitoneal space1. Despite
progress in multimodarity treatment, the prognosis
for the patients with soft tissue sarcoma is still poor.
It is well known that angiogenesis is essential for
primary  tumor growth,  invasion  and  metastasis  in
several kinds of cancer. With regards to soft tissue
sarcoma,  tumor  expression of  vascular  endothelial
growth factor (VEGF), a potent angiogenic factor,
was shown to correlate with malignant progression of
disease2,3. The facts that tumor progression is associ-
ated with angiogenesis lead to the concept of angio-
suppression as a new strategy for the treatment of
cancer patients4,7. Recent study demonstrated that
anti-angiogenic study using gene transfer of a cDNA
coding for angiostatin8, a potent angiogenic inhibitor,
suppressed the mouse fibrosarcoma tumor growth in
vivo9. This indicates that the growth of soft tissue sar-
coma is, at least in part, angiogenesis dependent and
anti-angiogenic therapy may be a novel approach for
the treatment of the patients with soft tissue sarcoma.
The angiogenesis inhibitor TNP-470 (AGM-1470)
is a synthetic analogue of fumagillin10 but has stronger
anti-angiogenic  activity  and  fewer  side  effects  than
fumagillin11. Actually some clinical trials have been
started for the treatment of cancer12–14. With regard to
the effects of TNP-470 for bone and soft tissue sar-
coma, several reports indicated that TNP-470 could
suppress the tumorigenicity and the establishment of
pulmonary metastasis in animal osteosarcoma15,16.
In the current study, we examined whether TNP-
470 could suppress the tumorigenicity of HT1080 fib-
rosarcoma tumor. Furthermore, to explore the interac-
tion of TNP-470 with tumor cells, we have investigated
whether the conditioned medium from the tumor cells
treated with TNP-470 can inhibit the proliferation and
motile activity of human endothelial cells. In addition,
we have examined the secretion of several angiogenic
factors from the tumor cells treated with TNP-470.
Materials and methods
Cells and cell culture
Human  fibrosarcoma  cell  line  HT1080,  human
umbilical  vein  endothelial  cell  (HUVEC)  (Sanko
Junyaku Co. Ltd., Tokyo, Japan) and spontaneous
transformed human  endothelial  cell line  ECV3017198 M. Kaya et al.
were maintained at 37ºC at 5% CO2 in Dulbecco’s
modified Eagle’s medium (DMEM) with 10% fetal
bovine serum (JRH Biosciences, Lenexa, KS) and
penicillin/streptomycin.
Materials
TNP-470 was obtained from Takeda Chemical Indus-
tries Ltd. (Osaka, Japan). In in vivo experiments, TNP-
470 was suspended in a vehicle composed of 0.5% eth-
anol plus 5% gum arabic in saline. In in vitro experi-
ments, TNP-470 was dissolved in dimethylsulfoxide.
Animals
Female BALB/c nu/nu mice, which originated from
the  Central  Institute  for  Experimental  Animals
(Kawasaki, Japan) were obtained from CLEA Japan
Inc. (Tokyo, Japan). Mice 6 weeks old that weighed
about 20g were used.
Assay of HT1080 tumor growth
HT1080 cells (23 106/0.1 ml in phosphate-buffered
saline) were s.c. injected into nude mice. TNP-470
(30 mg/kg) were given s.c. on alternate days for 4
weeks from day 1 after s.c. injection. The resulting
tumors were measured with calipers and tumor vol-
umes were  estimated using the  following  formula:
V=a3 b2/2 (V, volume; a, the longest diameter; b, the
shortest diameter).
Proliferation assay of HT1080 cells in vitro
HT1080 cells were plated on a 60 mm plastic dish on
day 0 (13 106) and cultured in DMEM supplemented
with 10% FCS with or without 10 ng/ml of TNP-
470. Cell growth was estimated on days 1 and 2 by
counting the total number of cells on dishes. Each
experiment was performed in triplicate.
Preparation of conditioned medium
First, 13 106 HT1080 cells were incubated with or
without 10 ng/ml of TNP-470 for 24 hrs. The cells
were  washed  twice  with  PBS  and  incubated  with
serum-free DMEM for 24 hrs. Condition medium
was collected and kept at –80ºC until use.
Endothelial cell proliferation assay in vitro
HUVEC or ECV304 cells were placed on a 60 mm
plastic dish on day 0 (13 106) and cultured in DMEM
supplemented with 10% FCS. On day 1, the medium
was replaced with condition medium from HT1080
cells treated with or without 10 ng/ml of TNP-470.
Cell growth was estimated on days 2 and 3 by count-
ing the total number of cells on dishes. Each experi-
ment was performed in triplicate.
In vitro motility assay
Transwell  culture  chambers  (Coaster  Corp.,  Cam-
bridge, USA) were used for the motility assay. HUVEC
or ECV304 cells (13 105) were suspended in condition
medium from HT1080 cells treated with or without
TNP-470 and added to the upper chamber. The lower
chamber contained DMEM supplemented with 10%
FCS and human cellular fibronectin (12.5 m g/ml, as a
chemoatractant).  Cells were incubated for  6  hrs. at
37ºC in a CO2 incubator. At the end of the incubation,
cells on the upper surface of the filter were completely
removed by wiping with a cotton swab. Cells were fixed
with 5% glutaraldehyde and stained with Giemsa solu-
tion. Cells that moved to the lower surface of the filter
were counted under a light microscope at a magnifica-
tion of 3 100. Each assay was done in triplicate.
Matrigel plug assay for the evaluation of angiogenesis
Mice in the tumor-removal and tumor-intact groups
were injected s.c. with 0.5 ml of Matrigel (Becton
Dickinson,  Bedford,  MA)  containing  200  ng  of
recombinant basic fibroblast growth factor (Upstate
Biotechnology, Lake Placid, NY). TNP-470 (30 mg/
kg)  was  given  s.c.  on  alternate  days  for  4  weeks.
Matrigel pellets were harvested four weeks after the
inoculation  and  reliquefied  by  incubation  at  4ºC
overnight in 300 m l of PBS. Matrigel neovasculariza-
tion was quantitatively determined by measuring the
hemoglobin content of the liquefied pellets (Drab-
kin’s method; Sigma Chemical Co. St Louis, MO).
Five mice were used in each group.
Angiogenic factors production
Angiogenic  factors,  VEGF  (vascular  endothelial
growth factor), bFGF (basic fibroblast growth factor)
and PlGF (placenta growth factor), concentrations of
conditioned medium  from  HT1080  cells  (13 105)
treated with or without TNP-470 were measured by
using  an  enzyme-linked  immunosorbant  assay  kit
(VEGF, IBL Fujioka, Japan; bFGF and PlGF, R &
D Systems, Minneapolis, MN).
Statistical analysis
Tumor volume, cell proliferation, motile activity, and
the serum levels of circulating factors were analyzed
using the Student’s t test. Statistical significance was
defined as p<0.05.
Results
Effect of TNP-470 on the growth of HT1080 tumor in 
vivo and the proliferation of HT1080 cells in vitro
The  ability  of  TNP-470  to  inhibit  the  neoplastic
growth in vivo was evaluated in nude mice inoculated
with  HT1080  cells by s.c.  injection. The  effect  ofSuppression of VEGF secretion by TNP-470 199
TNP-470 at the concentration of 30 mg/kg was com-
pared with the results of administration of a vehicle of
1% ethanol and 5% gum arabic in saline solution. As
shown in Figure 1A, TNP-470 significantly inhibited
the growth of HT1080 tumor (p<0.05). To examine
whether  TNP-470  can  suppress the  systemic ang-
iogenic  activity,  Matrigel  plug  neovascularization
assay was performed. The hemoglobin concentration
of Matrigel plugs inoculated into the nude mice of the
TNP-470 treated group was significantly lower than
those of control group (p<0.05) indicating that the
administration of TNP-470 could suppress the sys-
temic angiogenic activity in nude mice (Figure 1B).
We next examined whether TNP-470 affected the
proliferative activity of HT1080 cells in vitro. The
addition of  TNP-470,  however, could not  inhibit
the proliferation of HT1080 cells (Figure 2). These
findings indicate that TNP-470-mediated suppres-
sion of the tumorigenicity  of HT1080  tumor was
not due to the direct action of TNP-470 for the pro-
liferation of HT1080 cells.
Inhibitory effects of the conditioned medium from 
TNP-470-treated HT1080 cells on endothelial cell 
proliferation and migration
To  determine  whether  TNP-470  affects  sarcoma
cell-induced angiogenesis, we examined the effects of
the conditioned medium from HT1080 cells treated
with TNP-470 on the proliferation of HUVEC and
ECV304  cells. In this experimental series, we pre-
pared  the  conditioned  medium  as  described  in
“Materials  and Methods” in order to  rule out the
direct effects of TNP-470 on the endothelial cells. As
shown  in  Figure  3,  the  addition  of  conditioned
medium from HT1080 cells treated with TNP-470
to endothelial cells resulted in inhibition of endothe-
lial cell proliferation. Furthermore, the addition of
conditioned medium from HT1080 cells treated with
TNP-470 inhibited the motile activity of endothelial
cells (Figure 4).
Inhibitory effects of TNP-470 on VEGF production 
by HT1080 cell
Angiogenic factors are potent mitogen for endothe-
lial  cells18.  Among  angiogenic  factors,  VEGF,
bFGF and PlGF are considered to be most com-
monly secreted from the tumor cells. Because the
conditioned  medium  from  HT1080  cells  treated
with  TNP-470  inhibited  the  proliferation  of
Fig. 1. The effects of TNP-470 on the in vivo growth of HT1080 human fibrosarcoma cells. (a) HT1080 human fibrosarcoma cells 
(13 106) were s.c. injected into nude mice. Tumor volume were measured weekly. Data are means from 3 independent experiments ± 
SEM. (b) Matrigel plug neovascularization was quantitated by measuring the hemoglobin content of the pellets using Drabkin’s meth-
ods. Hemoglobin concentration was significantly lower in the mice of TNP-470 treated group. Columns, mean of 5 mice/group; bars, 
SE.
Fig. 2. The effects of TNP-470 on the proliferation of HT1080 
cells. HT1080 cells were incubated with TNP-470 (10 ng/ml) 
for 48 hrs. Cells were counted using hemocytometer. Data are 
means from 3 independent experiments ± SEM.200 M. Kaya et al.
HUVEC and ECV304  cells, we assessed whether
the  direct  action  of  TNP-470  on  HT1080  cells
could suppress the secretion of angiogenic factors
from the sarcoma cells. As shown in Figure 5, the
concentration of VEGF in cultures of HT1080 cells
treated with TNP-470 was significantly lower than
that  of  control  cells  (p<0.05).  The  treatment  of
TNP-470 had no effects on the secretion of bFGF
and  PlGF.  These  results  indicate  that  anti-ang-
iogenic activity of TNP-470 is mediated, at least in
part, the suppression of VEGF secretion from the
tumor cells.
Fig. 3. The effects of conditioned medium from HT1080 treated with TNP-470 on endothelial proliferation. HUVEC and ECV304 
were incubated with the conditioned medium from HT1080 treated with or without TNP-470 (10 ng/ml) for 48 hrs. Cells were counted 
using hemocytometer. Data are means from 3 independent experiments ± SEM.
Fig. 5. The effects of TNP-470 on the angiogenic factor pro-
duction by HT1080 cells. HT1080 human fibrosarcoma cells
(13 105) were cultured for 24 hrs. with or without TNP-470
(10 ng/ml). The concentration of VEGF, bFGF and PlGF
which were secreted into the culture media were assayed with
enzyme immunoassay kits. Data are means from 3 independent
experiments ± SEM.
Fig. 4. The effects of conditioned medium from HT1080 treated
with TNP-470 on endothelial migration. Motility of HUVEC
and ECV304 cells suspended in the conditioned medium from
HT1080  treated  with  or  without  TNP-470  (10  ng/ml)  was
determined by chemotaxis assays using a transwell cell culture
chamber. Data  are  means from  3 independent experiments ±
SEM.Suppression of VEGF secretion by TNP-470 201
Inhibitory effects of TNP-470 on tumor-mediated 
angiogenesis
We finally examined whether angiogenesis-inducing
ability  of  the  conditioned  medium  from  HT1080
cells treated with TNP-470 was suppressed using a
Matrigel plug neovascularization assay. In brief, Mice
were injected s.c. with 0.5 ml of Matrigel containing
50 m l of the conditioned medium from HT1080 cells
treated with or without TNP-470. Matrigel neovas-
cularization was quantitatively determined by meas-
uring the hemoglobin content of the liquefied pellets.
The  hemoglobin  concentration  of  Matrigel  plugs
with  the  conditioned medium from  HT1080  cells
treated with TNP-470 was significantly lower than
those from control cells (p<0.05) (Figure 6).
Discussion
In the present study, we have demonstrated that 1)
TNP-470 can inhibit the tumorigenicity of HT1080
fibrosarcoma  cells,  2)  conditioned  medium  from
HT1080 cells treated with TNP-470 can inhibit the
proliferation and motile activity of human endothelial
cells, and 3) TNP-470 can downregulate the secre-
tion of VEGF from HT1080 cells. These results indi-
cate that the downregulation of VEGF secretion from
tumor cells by TNP-470 caused the suppression of
tumor neoangiogenesis which lead to the inhibition of
HT1080 tumor growth.
With regard to the mechanisms of antiangiogenic
activity  of TNP-470, several reports indicated that
TNP-470 could act on endothelial cells directly and
inhibit  neovascularization  by  preventing  its
proliferation19–24. On the other hand, it has been also
reported that TNP-470 could act on the tumor cells
directly and downregulated the production of ang-
iogenic  factors  by  tumor  cells,  thereby  impedes
tumoral angiogenesis25–27.
Recent  study  demonstrated  that  the  effects  of
TNP-470 was more remarkable on angiogenic factor-
positive  tumors than  on angiogenic factor-negative
tumors. And this suppressive effect was accompanied
by the downregulation of the angiogenic factor pro-
duction by tumor cells suggesting the possibility that
the direct action of TNP-470 on tumor cells is more
significant than that on the endothelial cells27.
Vascular  endothelial  growth  factor  (VEGF)  is  a
homodimeric protein recently identified as a mitogen
for endothelial cells in vitro, and an angiogenesis-pro-
moting factor in vivo28–31. The data we have shown
here indicates that TNP-470 could suppress the secre-
tion of VEGF from HT1080 cells resulting in the inhi-
bition  of  endothelial  cell  proliferation  and  motility.
Thus, the inhibitory effects of TNP-470 for the tumor-
igenicity of HT1080 tumors considered to be, at least
in part, due to the suppressed secretion of VEGF from
the tumor cells. Furthermore, the secretion of other
angiogenic factors, bFGF and PlGF, have not been
downregulated after the treatment of TNP-470 indi-
cating that VEGF is one of the potent angiogenic fac-
tors which are affected by the treatment of TNP-470.
We have recently demonstrated that the expression
of VEGF in primary osteosarcoma is significantly cor-
related with the development of pulmonary metastasis
and poor prognosis32. These findings suggest the pos-
sibility that VEGF-mediated angiogenesis may play a
critical  role  in the  progression of  sarcoma.  Several
reports have also demonstrated that  TNP-470  suc-
cessfully suppressed the tumorigenicity and develop-
ment of pulmonary metastasis in experimental animal
sarcoma  models15,16.  Now,  with  the  current  data
which we have demonstrated here, it is conceivable
that  anti-angiogenic  drugs  like  TNP-470  could be
indicated for the treatment of VEGF positive sarcoma.
In conclusion, the present study provides evidence
for the molecular mechanism of the anti-angiogenic
activity of TNP-470 and also the possibility that anti-
angiogenic drugs could be employed for the treat-
ment of soft tissue sarcoma, targeting angiogenesis as
a new therapeutic strategy.
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